{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:26:53Z","timestamp":1790029613710,"version":"4.0.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,21]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To assess safety of baricitinib in Japanese patients with rheumatoid arthritis (RA) in real-world clinical practice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This all-case postmarketing surveillance study included patients initiating baricitinib for RA from September 2017 to April 2019. Treatment duration was recorded. Safety data were collected for up to 3\u2009years from initiation (up to 4\u2009weeks postdiscontinuation in discontinuing patients).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Safety analyses included 4720 patients; 2580 (54.7%) were \u226565\u2009years old. Baricitinib persistence rate was 45.4% (3-year Kaplan\u2013Meier analysis); the most common discontinuation reason was insufficient effectiveness (n\u2009=\u20091005, 21.3%). Serious adverse events occurred in 600 patients [incidence rate (IR) 10.42\/100 patient-years (PY); 95% confidence interval, 9.76\u201311.09]. There were 39 deaths [IR 0.43 (0.30\u20130.57)\/100 PY]. Adverse events of special interest IRs per 100 PY were herpes zoster 4.68 (4.22\u20135.14), serious infection 3.05 (2.68\u20133.41), malignancy 1.09 (0.87\u20131.30), major adverse cardiovascular events 0.35 (0.23\u20130.48), and venous thromboembolism 0.25 (0.15\u20130.36). IRs did not increase with prolonged exposure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>No new safety concerns were identified during this 3-year postmarketing surveillance study of baricitinib in Japanese patients with RA. Patients and clinicians should be cognizant of herpes zoster and other serious infection risks during baricitinib treatment, especially in the first 6\u2009months.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roae064","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T17:59:07Z","timestamp":1723226347000},"page":"215-224","source":"Crossref","is-referenced-by-count":14,"title":["Safety of baricitinib in Japanese patients with rheumatoid arthritis in clinical use: 3-year data of all-case postmarketing surveillance study"],"prefix":"10.1093","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9085-5250","authenticated-orcid":false,"given":"Nami","family":"Okamoto","sequence":"first","affiliation":[{"name":"Department of Paediatrics, Osaka Rosai Hospital , Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Atsumi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University , Hokkaido,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3052-787X","authenticated-orcid":false,"given":"Michiaki","family":"Takagi","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Yamagata University Faculty of Medicine , Yamagata,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobunori","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Aichi Medical University , Aichi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Saitama Medical University , Saitama,","place":["Japan"]},{"name":"Keio University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1729-2954","authenticated-orcid":false,"given":"Naoto","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, Juntendo University Faculty of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuo","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Ueno Dialysis Clinic , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6789-1739","authenticated-orcid":false,"given":"Ayako","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Center for Rheumatic Diseases, Mie University Hospital , Mie,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Wakayama Medical University , Wakayama,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Matsuno","sequence":"additional","affiliation":[{"name":"Matsuno Clinic for Rheumatic Diseases , Toyama City,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taeko","family":"Ishii","sequence":"additional","affiliation":[{"name":"Japan Drug Development & Medical Affairs, Eli Lilly Japan K.K. , Kobe,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Tsujimoto","sequence":"additional","affiliation":[{"name":"Japan Drug Development & Medical Affairs, Eli Lilly Japan K.K. , Kobe,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Japan Drug Development & Medical Affairs, Eli Lilly Japan K.K. , Kobe,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Machiko","family":"Minatoya","sequence":"additional","affiliation":[{"name":"Japan Drug Development & Medical Affairs, Eli Lilly Japan K.K. , Kobe,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health , Kitakyushu,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8352-6136","authenticated-orcid":false,"given":"Masataka","family":"Kuwana","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,9]]},"reference":[{"key":"2025030423303632500_R1","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"2025030423303632500_R2","doi-asserted-by":"crossref","first-page":"ITC1","DOI":"10.7326\/AITC201901010","article-title":"Rheumatoid arthritis","volume":"170","author":"Sparks","year":"2019","journal-title":"Ann Intern Med"},{"key":"2025030423303632500_R3","doi-asserted-by":"crossref","DOI":"10.3390\/cells10112857","article-title":"Management of rheumatoid arthritis: an overview","volume":"10","author":"Radu","year":"2021","journal-title":"Cells"},{"key":"2025030423303632500_R4","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025030423303632500_R5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2025030423303632500_R6","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025030423303632500_R7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/14397595.2017.1307899","article-title":"Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: a 52-week, randomized, single-blind, extension study","volume":"28","author":"Tanaka","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2025030423303632500_R8","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"2025030423303632500_R9","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2022-eular.4546","article-title":"Long-term efficacy of baricitinib in patients with rheumatoid arthritis who have had inadequate response to csDMARDs: results from RA-BEYOND up to 7 years of treatment [EULAR 2022 European Congress of Rheumatology, Abstract POS0701]","volume":"81","author":"Caporali","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025030423303632500_R10","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/annrheumdis-2021-221276","article-title":"Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database","volume":"81","author":"Taylor","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025030423303632500_R11","first-page":"201","article-title":"Evaluation of VTE, MACE, and serious infections among patients with RA treated with baricitinib compared to TNFi: a multi-database study of patients in routine care using disease registries and claims databases","volume":"10","author":"Salinas","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2025030423303632500_R12","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"2025030423303632500_R13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025030423303632500_R14","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/mr\/roac089","article-title":"Safety and effectiveness of baricitinib for rheumatoid arthritis in Japanese clinical practice: 24-week results of all-case post-marketing surveillance","volume":"33","author":"Takagi","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2025030423303632500_R15","article-title":"Olumiant\u00ae tablets 4mg\/2mg package insert (4th edition)","author":"Eli Lilly Japan","year":"2021"},{"key":"2025030423303632500_R16","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1080\/14397595.2019.1583711","article-title":"Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: an integrated analysis of phases 2 and 3 trials","volume":"30","author":"Harigai","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2025030423303632500_R17","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/art.23112","article-title":"The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom","volume":"57","author":"Smitten","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2025030423303632500_R18","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025030423303632500_R19","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20936059","article-title":"JAK inhibitors and infections risk: focus on herpes zoster","volume":"12","author":"Sunzini","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2025030423303632500_R20","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1136\/annrheumdis-2019-216852","article-title":"Infections in baricitinib clinical trials for patients with active rheumatoid arthritis","volume":"79","author":"Winthrop","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025030423303632500_R21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/rheumatology\/kes305","article-title":"The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment","volume":"52","author":"Listing","year":"2013","journal-title":"Rheumatology"},{"key":"2025030423303632500_R22","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3899\/jrheum.141210","article-title":"Longterm safety of tocilizumab: results from 3 years of followup postmarketing surveillance of 5573 patients with rheumatoid arthritis in Japan","volume":"42","author":"Yamamoto","year":"2015","journal-title":"J Rheumatol"},{"key":"2025030423303632500_R23","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.berh.2019.03.011","article-title":"Malignancy and rheumatoid arthritis: epidemiology, risk factors and management","volume":"32","author":"De Cock","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2025030423303632500_R24","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/ard-2023-224049","article-title":"JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications","volume":"82","author":"Russell","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025030423303632500_R25","article-title":"Malignancy outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: results from a 10-year international post-marketing study","volume":"64","author":"Simon","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"2025030423303632500_R26","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/art.40841","article-title":"Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis","volume":"71","author":"Taylor","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025030423303632500_R27","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1136\/ard-2022-222824","article-title":"Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study","volume":"82","author":"Hoisnard","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025030423303632500_R28","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa2206916","article-title":"Global effect of modifiable risk factors on cardiovascular disease and mortality","volume":"389","author":"Magnussen","year":"2023","journal-title":"N Engl J Med"},{"key":"2025030423303632500_R29","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3899\/jrheum.150613","article-title":"Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12-week, double-blind, randomized placebo-controlled study","volume":"43","author":"Tanaka","year":"2016","journal-title":"J Rheumatol"},{"key":"2025030423303632500_R30","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/1756-185X.13974","article-title":"Prevalence of patients with rheumatoid arthritis and age-stratified trends in clinical characteristics and treatment, based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan","volume":"23","author":"Nakajima","year":"2020","journal-title":"Int J Rheum Dis"},{"key":"2025030423303632500_R31","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.3899\/jrheum.151212","article-title":"Adherence and persistence with methotrexate in rheumatoid arthritis: a systematic review","volume":"43","author":"Curtis","year":"2016","journal-title":"J Rheumatol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roae064\/59633514\/roae064.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/35\/2\/215\/59633514\/roae064.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/35\/2\/215\/59633514\/roae064.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T23:30:52Z","timestamp":1741131052000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/35\/2\/215\/7730394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,9]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,8,9]]},"published-print":{"date-parts":[[2025,2,21]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roae064","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,8,9]]}}}